Introduction
Genes that function in epigenetic regulation (epigenes), including those involved in chromatin remodeling and histone modifications, are increasingly being identified in the etiology of a variety of neurodevelopmental disorders. Two CHARGE syndrome is characterized by Coloboma, Heart defects, Atresia of the choanae, Retardation of growth and development, Genital hypoplasia, and Ear abnormalities including deafness and vestibular disorders. Kabuki syndrome is characterized by a typical facial gestalt, postnatal growth deficiency, congenital heart defects, hearing loss and intellectual disability as well as skeletal, dermatoglyphic, genitourinary, and ophthalmologic anomalies (including coloboma). There is extensive clinical overlap between these two syndromes and clinical distinction can be particularly challenging in early life as the characteristic facial features of Kabuki syndrome often become apparent with age. 3, 4 A molecular link between CHD7
and KMT2D function has been proposed via their known interaction with members of the WAR complex (WDR5 [WD-repeat protein 5], ASH2L [absent, small, homeotic discs-2-like], and also RBBP5 [retinoblastoma-binding protein-5]), which has been shown to be involved in histone methylation. 5, 6 It has been suggested that CHD7 and KMT2D might regulate a common subset of genes via their interaction with the WAR complex, which might explain the overlapping features in CHARGE and Kabuki syndromes. 7 We and others have previously demonstrated that loss of function (LOF) mutations in epigenes can be associated with specific patterns of DNA methylation (DNAm) alterations that constitute unique signatures. [8] [9] [10] [8] [9] [10] Moreover, for NSD1 we have shown that genes encoding proteins in growth and neurodevelopmental pathways are highly represented in the DNAm signature reflecting the pathophysiology of the disorder. 8 We hypothesized that comparison of genome-wide DNAm alterations in individuals with heterozygous LOF mutations in CHD7 and KMT2D, respectively, would identify two disease-specific DNAm signatures that would include common target genes and biological pathways, reflecting the clinical overlap of these two conditions, as well as distinct target genes reflecting divergent clinical features.
Here we analyze DNAm using whole blood from individuals with a clinical diagnosis of either CHARGE or Kabuki syndrome with LOF mutations in CHD7 (CHD7 LOF Cohort with CHD7 and KMT2D Sequence Variants, Excluding LOF Individuals with CHD7 (n ¼ 13) or KMT2D (n ¼ 10) VUS including missense and splice site variants were recruited from the same institutions as the CHD7 and KMT2D Discovery Cohorts (see above). Independent in silico prediction algorithms, namely PolyPhen-2, 12 SIFT, 13 Mutation Taster, 14 and ESE finder 15, 16 were used to evaluate the pathogenicity of the mutations in each case (Tables 1 and 2) . Phenotypic information available for the individuals is provided in Tables S3 and S4 . Individuals with CHD7 sequence variants underwent clinical classification utilizing the criteria established by Verloes 17 and Hale 18 (Table 1) .
Control DNA Samples
Age-and sex-matched controls for our discovery and validation cohorts were obtained from three sources (Table S6) . These included the Simons Simplex Collection (SSC; Simons Foundation Autism Research Initiative). 19 The Hospital for Sick Children, and The University of Michigan (Dr. Gregory Hanna). 20 The controls were screened using various neurodevelopmental assessments. 19, 20 DNAm Data from Public Databases Publically available Illumina HumanMethylation450 microarray data for an additional 162 blood controls, which were not expected to contain pathogenic mutations in either CHD7 or KMT2D, were downloaded from the Gene Expression Omnibus (GEO) data repository, chosen from individuals younger than 50 years of age in five GEO series (GEO: GSE32148, GEO: GSE40279, GEO: GSE41169,  GEO: GSE46648, GEO: GSE53128; see Table S7 ).
DNAm Data Processing
DNA samples were converted using sodium bisulfite (EpiTect PLUS Bisulfite Kit, QIAGEN). The sodium bisulfite converted DNA was then hybridized to the Illumina Infinium HumanMethylation450 BeadChip Array to interrogate over 480,000 CpG sites in the human genome. For both the Discovery and Validation cohorts, cases and controls were randomized on the arrays (modified from 21 ). Illumina Genome Studio software was used to perform control probe normalization and background subtraction and to extract DNAm values (b values) for each CpG, which represent the percentage of methylated cytosines. These b values ranged between 0 (no methylation) and 1 (full methylation). We excluded probes located on sex chromosomes, autosomal probes that cross-react with sex chromosome probes, non-specific probes, and probes targeting CpG sites within 5bp of a SNP that has a minor allele frequency above 1%. 22, 23 Subsequent analyses were performed on the remaining 363,979 probes.
CHD7
LOF and KMT2D
LOF DNAm Signatures
Differential DNAm between individuals with LOF mutations and controls at individual CpGs was identified using three criteria. First, we applied regression modeling implemented in the limma Bioconductor package to detect statistically significant differences in DNAm (false discovery rate [FDR] corrected p value < 0.01) attributed to either CHD7 LOF or KMT2D LOF versus controls, while accounting for sex and age ( Figure S1 ) as confounding factors in the model design matrix. 24 The limma models were applied to DNAm data logit-transformed into M-values. 25 Figure S2 ). The CpG sites that satisfied all three criteria defined the CHD7 LOF and KMT2D LOF DNAm signatures, respectively (Tables S8 and S9 ).
Building Classification Models with the CHD7 LOF and
KMT2D

LOF DNAm Signatures
Using the two DNAm signatures, we developed predictive models for scoring individuals with CHD7 or KMT2D sequence variants, based on their DNAm profiles. As the DNAm signatures for CHD7 LOF and KMT2D LOF often appeared in groups corresponding to the same gene or region, the CpG sites were filtered for redundancy in order to be used as predictive data features for the respective models. We applied R caret software package to identify highly correlated CpGs and removed redundant data features (using the default threshold of 0.90 correlation in the findCorrelations function of caret). The remaining CpG sites were used to build the CHD7 LOF and KMT2D LOF classification models.
We then built a support vector machine (SVM) model with linear kernel, using the non-redundant DNAm signatures as data features to predict the putative pathogenicity of each sequence variant. Model training was performed by the R kernlab software package via caret. The training set comprised the CHD7 LOF or the KMT2D LOF and control samples from the Discovery Cohort. The model was set to return a quantitative predictive score between 0 and 1. The SVM scores were derived in kernlab using internally randomized cross-validation and thus exhibit slight variability. Therefore for each individual we determined the average score over 100 scoring trials. We then applied these models to samples from the Validation Cohort, another cohort with CHD7 or KMT2D sequence variants (excluding LOF mutations) and GEO controls. High scores indicate putative pathogenicity of sequence variants in CHD7 or KMT2D, and low scores suggest that the sequence variants are benign. Figure S3 ). Our goal was to verify that none of the blood-cell subtypes were given high scores by either CHD7 LOF or KMT2D LOF predictive models, confirming the lack of a confounding effect between blood-cell type composition and the DNAm signaturebased predictions.
Assessment of Blood Cell Type Composition Effect
Differentially Methylated Regions in the CHD7 and KMT2D Discovery Cohorts
To find genomic regions with DNAm differences in CHD7 LOF or KMT2D
LOF
, we used the bump hunting method, 27 which strengthens the detection of regional differences by combining differential-methylation patterns across neighboring CpG sites. 28 The bump hunting design matrix accounted for the potential confounding effects of the sex and age factors. The analysis initially considered CpGs with Db > 5% by magnitude between cases and controls as candidates for the differentially methylation regions (DMRs), with gaps no more than 500 bp between neighboring CpGs. Statistical significance was established using 1,000 randomized bootstrap iterations, as is recommended in the Bioconductor bumphunter package documentation when accounting for confounders. The resulting DMRs were post-filtered to retain only those with p value < 0.01 and average methylation difference Db > 10% by magnitude across the DMR. To further improve robustness, we also required these DMRs to comprise at least three neighboring CpGs, of which at least one has been already been included in the DNAm signature set for either CHD7 LOF or KMT2D LOF , as described above (Tables S10 and S11 ). DMRs are presented using visualization methods adapted from DMRcate software ( Figure S4 ). 29 
Functional Enrichment Analysis
To identify prominent functional enrichment patterns, we analyzed the list of differentially methylated CpGs in the context of wider genomic regions using GREAT. 30 We retained only the Gene Ontology (GO) Biological Process 31 functional categories for which at least three genes (including their genomic neighborhoods) were targeted by the CHD7 LOF or KMT2D LOF specific DNAm signatures (Tables S12 and S13 ). The background set of probes to which the comparison was made was defined as the 363,979 autosomal CpGs used as the initial input to our analysis pipeline. All p values were FDR corrected.
DNAm Validation by Sodium Bisulfite Pyrosequencing
Differential DNAm between the CHD7 LOF and KMT2D LOF individuals in the Discovery Cohorts and matching controls was validated for selected genomic loci using pyrosequencing assays. These assays were designed using QIAGEN Assay Design Software v1.0.6 to targetspecific CpGs identified by the microarray experiment, as well as adjacent sites (Table S14) (Tables S8  and S9 ). Two SVM classification models were then built using the CHD7 and KMT2D Discovery Cohort samples as training sets and the corresponding non-redundant DNAm signatures as data features.
CHD7
LOF and KMT2D LOF DNAm Signatures Are
Independent of Blood Cell Type Composition
Both CHARGE and Kabuki syndromes can be associated with immune dysfunction although the sub-populations of T cells that are potentially altered represent a small fraction of the total lymphocytes. 32, 33 To ensure that the predictive models were not affected by the variation in blood cell types, the two predictive models were applied to DNAm data from normal whole blood, peripheral blood mononuclear cells (PBMC), granulocytes, and isolated cell populations (CD4
. 26 Prediction results demonstrated that all individual cell types received low predictive scores, placing them near other controls in our data ( Figure S3 ). This suggests that the prediction of either CHD7 LOF or KMT2D LOF status using the respective DNAm signatures is not influenced by a particular blood cell type within a sample. Clinical blood counts and differentials were available for 7 individuals with CHD7 mutations (3 LOF; 4 sequence variants) and for 2 individuals with KMT2D mutations (1 LOF and 1 sequence variant), and all were within the normal range. , confirming the specificity of the second model ( Figure 2 ). Next we assessed the specificity of the predictive analysis on the collection of control blood DNAm data extracted from the GEO repository. All 162 GEO samples had low prediction scores for both CHD7 LOF and KMT2D LOF , i.e., they were predicted not to have pathogenic mutations in CHD7 or KMT2D by the corresponding models, demonstrating 100% specificity of the DNAm signatures ( Figure 2 ).
Validation of CHD7
LOF and KMT2D LOF DNAm
Classification Signatures Using a Blinded Cohort Next we applied the predictive models for CHD7 LOF and KMT2D LOF DNAm classification signatures in a blinded fashion to a cohort of individuals with either CHD7 or KMT2D mutations classified as pathogenic, likely pathogenic or variants of unknown significance (VUS; Validation Cohort). After the prediction scores were generated, the mutation classification was unblinded for comparison to the reported variant classification (Figure 3 ). The CHD7 LOF DNAm signature predictive model generated high scores for all of the CHD7 mutation samples (n ¼ 20) that were classified as pathogenic or likely pathogenic. The same was true of the KMT2D LOF model (n ¼ 8). Thus, both predictive models demonstrated the ability to correctly classify pathogenic mutations in their respective genes, CHD7 or KMT2D (100% sensitivity), while giving low scores to samples with mutations in the other gene and to all controls in the Validation Cohort (100% specificity). The Validation Cohort included one individual with a mutation in KDM6A, a second gene in which mutations are associated with Kabuki syndrome. 34 Interestingly, the KDM6A mutation received a high score from the KMT2D LOF DNAm classification signature model, indicating that it is more similar to KMT2D LOF than controls or CHD7 LOF .
Analysis of Sequence Variants in CHD7 and KMT2D Using Gene-Specific DNAm Classification Signatures
The predictive models were next applied to cohorts of individuals with CHD7 and KMT2D sequence variants of uncertain significance (VUS) that included missense and splice site mutations (Figure 4 ; Tables S1 and S2 LOF and KMT2D LOF DNAm Classification Signatures on a Blinded Cohort We derived the scores for each sample using the two predictive models built for the CHD7 LOF and KMT2D LOF DNAm classification signatures (x axis and y axis, respectively; see Figure 2 ), for a validation set of DNAm samples. This set included both pathogenic mutations and VUS in CHD7 (red squares), KMT2D (blue triangles) and KDM6A (turquoise diamond). The mutation and their pathogenicity were initially blinded and were revealed only after the prediction scores were determined. Importantly, all CHD7 mutations received low scores by the KMT2D-specific predictive model, and vice versa. Pathogenic mutations in CHD7 (filled red squares) received high scores from the CHD7 LOF model, and pathogenic mutations in KMT2D (filled blue triangles) received very high scores from the KMT2D LOF model. Interestingly, a pathogenic mutation in the Kabuki-associated gene KDM6A also received a very high score from the KMT2D LOF model, indicating a potential methylation-signature overlap between these two genes.
and met a clinical diagnosis for CHARGE using the Hale criteria but the CHD7 LOF DNAm classification signature predicted this to be a benign CHD7 variant. This variant was an inherited synonymous mutation. 27 detected consistent patterns of DNAm gain or loss in the vicinity of these genes (Table S10 ). Enrichment analysis of the probes within the CHD7 LOF DNAm signature confirmed a statistically significant over-representation in GO Biological Process 31 categories related to growth and embryonic development of the brain, ear, digestive, endocrine, and neural systems, as well as additional functional categories that are highly relevant to the phenotypic features associated with CHARGE syndrome (Table S12 ). The KMT2D LOF CpG sites were located within the bodies or promoter regions of 105 known genes (Table  S9) . Among these, multiple CpG sites mapped to HOTAIRM1, homeobox A4 (HOXA4 [MIM: 142953]), HOXA5, and SLITRK5. These genes were also identified as corresponding to KMT2D LOF associated differentially methylated regions detected by bump hunting (Table  S11 ). Enrichment analysis of the probes within the KMT2D LOF DNAm signature confirmed a statistically significant over-representation in GO biological processes categories related to skeletal, lung and digestive system development; as well there were functional categories similar to those observed for the CHD7 LOF signature including pattern specification and embryonic morphogenesis (Table S13) Figure S4A ). The shared CpG sites near SLITRK5 demonstrated DNAm changes in opposite directions in the two signatures, with a loss of DNAm Figure 4 . Sequence Variants in CHD7 and KMT2D Sorted Using the CHD7 LOF and KMT2D LOF DNAm Classification Signatures We derived the scores for each individual using the two models generated for CHD7 LOF and KMT2D LOF DNAm classification signatures (x axis and y axis, respectively; see Figure 2 ), for a set of 13 mutation variants in CHD7 (red crossed circles) and 10 mutation variants in KMT2D (blue crossed squares). The details of the sample classification are shown in Tables 1 and 2. in CHD7
LOF but gain of DNAm in KMT2D
LOF
. For SLITRK5, 3 CpG sites (cg16787483, cg24626752, and cg09823859; Figures 5D-5F) were validated using pyrosequencing. An average loss of DNAm of 20%, 14%, and 12% in the CHD7 LOF samples was confirmed, whereas an average gain of DNAm of 21%, 24%, and 24% was confirmed in KMT2D LOF samples. This finding was confirmed by bumphunting in the overlapping DMRs ( Figure S4B ). DNAm was also validated for CpG sites in genes specific to each DNAm signature. For the CHD7 LOF DNAm signature two CpG sites in FOXP2 (cg18546840 and cg18871253) were selected because of the critical role of FOXP2 in brain and craniofacial development. 36, 37 Both of these CpG sites exhibit an average loss of DNAm of 15% ( Figures 5G and 5H ). For the KMT2D LOF DNAm signature a CpG site in MYO1F (cg15254671) with an average 33% loss of DNAm ( Figure 5I ) was validated. This CpG site, along with four others in the same CpG island (spanning exon 23 to 24), carry chromatin marks classified as a promoter or enhancer in different cell types.
38,39
Discussion
We have identified two unique DNAm signatures associated with loss of function mutations in CHD7 (CHD7  LOF ) and KMT2D (KMT2D LOF ), further enhancing our understanding of the critical role of epigenetic dysregulation in neurodevelopmental disorders. These two gene-specific signatures demonstrate 100% specificity and 100% sensitivity, enabling differentiation between pathogenic and benign mutations in CHD7 and KMT2D, respectively. That is, these DNAm signatures can function as tools to classify variants of unknown significance (VUS) in these genes. Interestingly, comparisons of the differentially methylated sites within the CHD7 LOF and KMT2D
LOF
DNAm signatures provide evidence that CHD7 and KMT2D regulate common biological pathways likely reflecting the clinical overlap between CHARGE and Kabuki syndromes.
Functional Roles of CHD7 and KMT2D
Mutations in CHD7 were initially identified as the etiology of CHARGE syndrome in 2004. 1 Since that time, much has been learned regarding the biological function of this gene. CHD7, an ATP-dependent chromodomain helicase chromatin remodeling protein is involved in the formation of several large protein complexes that regulate the movement of nucleosomes along DNA, and as such affects the activity of numerous signaling pathways during embryonic development. 40 These CHD7-containing protein complexes bind to DNA at specific sites, the majority of which overlap with regulatory elements such as gene promoters or enhancers. 41, 42 The epigenetic effects of CHD7 on chromatin and gene regulation appear to vary both temporally and spatially, depending largely upon the function of the protein complex with which it interacts (for review see 43 ). CHD7 is expressed in embryonic stem cells; its expression becomes restricted to specific tissues, including the brain, eye, heart, and ear, during differentiation. 44 Gene-expression studies in mouse embryos carrying a homozygous deletion of Chd7 demonstrate significant expression differences in many genes important for brain development. 45 Mutations in KMT2D were initially identified as the major cause of Kabuki syndrome in 2010. belongs to the family of mixed-lineage leukemia (MLL) genes, which are involved in controlling other genes essential for embryogenesis, including the HOX genes. 47, 48 In a mouse model of Kabuki syndrome, heterozygous disruption of Kmt2d is associated with a genome-wide reduction of H3K4 tri-methylation. 49 Histone methylation patterns in cardiac tissue from embryos with homozygous deletions of Kmt2d show a global decrease in H3K4 mono-and dimethylation, when compared to controls, suggesting that KMT2D functions at both enhancers and gene promoters to regulate gene expression. The challenges in establishing a clinical diagnosis of CHARGE syndrome using existing diagnostic criteria (Table 1) are highlighted by data for four individuals in the current study, that demonstrate incongruities between the criteria-based clinical classifications of CHARGE syndrome and our CHD7 LOF DNAm classification signature predictions. Specifically, three individuals who did not meet clinical criteria for a diagnosis of CHARGE syndrome were identified to have the DNAm signature (predicting pathogenicity) and one individual who did meet clinical criteria for a diagnosis of CHARGE syndrome did not have the DNAm signature (predicting a benign variant). Existing in silico prediction tools often provide different and contradictory results as seen for several of the individuals in our CHD7 variant cohort. 54 We propose that our CHD7 LOF DNAm classification signature could be used as a functional molecular test to aid in the interpretation of the pathogenicity of CHD7 sequence variants, providing a valuable tool to facilitate in the diagnosis of CHARGE syndrome. Similarly, the KMT2D LOF DNAm classification signature could be used to assess the pathogenicity of KMT2D sequence variants (Table 2 ). For example, in the case of the two individuals with KMT2D VUS, the DNAm classification signature provided functional molecular validation for a suspected clinical diagnosis when sequence analysis did not provide a definitive answer. For individuals reported to have putative pathogenic variants in CHD7, 17% do not fulfill diagnostic criteria for CHARGE syndrome, further demonstrating the phenotypic variability and the imperfect alignment between clinical classification and molecular test data. 55, 56 Further, although pathogenic mutations in CHD7 are identified in 90% of individuals fulfilling Blake's criteria, only 65%-70% of individuals with typical or suspected CHARGE syndrome are identified to have a pathogenic CHD7 mutation. 55, 57 Similarly, only $70% of individuals with a clinical diagnosis of Kabuki syndrome are identified to have pathogenic mutations in KMT2D or KDM6A 58 . It is not clear whether the missing 30% of mutations occur in promoters or enhancers not identified by current sequencing techniques or if there might be locus heterogeneity. The CHD7 LOF and KMT2D LOF DNAm signatures could provide a means of enhancing the molecular diagnostic rates for these syndromes, because they could detect loss of function mutations that might not be detected by current sequence-based testing. In future, further validation of the clinical utility of these signatures could be derived from RNA sequence-based functional assays.
The utility of DNAm signatures for the epigenes CHD7 and KMT2D constitute a generalization of our previous work with epigenes, in which we demonstrated the utility of a DNAm signature in classifying VUS in NSD1 associated with Sotos syndrome. 8 The NSD1-specific 4, 61, 62 The genes associated with CHARGE (CHD7) and Kabuki (KMT2D and KDM6A) syndromes all play a role in chromatin remodeling. Evidence supporting a functional connection between CHD7 and KMT2D comes from studies showing that both these protein interact with members of the WAR complex (WDR5, RBBP5, and ASH2L). 6, 7, 63 On the basis of these findings, it was suggested that CHD7 and KMT2D regulate a common subset of genes. 7 Our finding that the unique CHD7 LOF and KMT2D LOF DNAm signatures have common CpG targets, specifically within HOXA5 and SLITRK5, provides additional evidence for molecular mechanistic connections between CHARGE and Kabuki syndromes and also provides important functional data to explain the pathophysiologic basis of the overlapping features in these two conditions. Our previous work on NSD1 demonstrated the relevance of the DNAm targets in blood to our understanding of the pathophysiology of the disease. In the case of NSD1 loss of function mutations, DNAm gene targets were enriched for neural and cellular development pathways, reflecting the cardinal features of Sotos syndrome (overgrowth and developmental delay). 8 Our finding that the CHD7 and KMT2D DNAm targets appear to relate to genes involved in the embryonic development of cell types and tissues demonstrating malformations in CHARGE and Kabuki syndromes further supports the functional significance of these DNAm signatures and provides valuable data relevant to the pathophysiology of these conditions. Both CHD7 and KMT2D have been previously linked to expression of various homeobox-containing genes. The homeobox (HOX) genes encode highly conserved transcription factors that are expressed in a spatially and temporally regulated manner during development. 64 HOX expression during development is tightly regulated in part by chromatin structure and epigenetic modifications, including DNAm. 65 In the mouse, the developing neural tube of Chd7 À/À embryos also showed altered expression of other homeobox genes, such as orthodenticle homeobox 2 (Otx2) and gastrulation brain homeobox 2 (Gbx2 KMT2D has also been shown to bind to DNA in the HoxA cluster in mouse embryonic-stem-cell-derived cardiomyocytes. 47 The finding that HOXA5 is regulated by both CHD7 and KMT2D provides us with further clues to the pathophysiology of CHARGE and Kabuki syndromes. In both the CHD7 LOF and KMT2D LOF DNAm signatures, a gain in DNAm was observed at the HOXA5 promoter. Functional studies in a wide range of vertebrate species have established the conserved roles of HOX genes as transcription factors that regulate axial patterning of the developing embryo. 68 A study of the mouse promoter
HoxA5 showed that it is unmethylated in specific embryonic tissues, including liver, intestine, and spleen. 69 In those same tissues postnatally, the HoxA5 promoter becomes completely (spleen), or partially (intestine) unmethylated, or remains unmethylated (liver). Therefore, DNAm appears to be a crucial element in the developmental regulation of Hox activity postnatally. Our findings of a 20% increase in DNAm is likely to be functionally relevant given data from a mouse model wherein a high-fat diet is associated with a 25% increase in DNA methylation of the Hoxa5promoter in adipose tissue resulting in a significant reduction in mRNA and protein expression of this gene. 70 Some of the clinical features shared by CHARGE and Kabuki syndromes could be mediated by reduced expression of HOXA5. Based on functional studies of HOXA5 in mice, we propose that these could include growth deficiency, skeletal and limb anomalies, renal dysgenesis, and neural development. [71] [72] [73] [74] [75] In one mouse model with heterozygote Hoxa5 truncating mutations, the mutant mice were phenotypically indistinguishable from their wild-type littermates but on further evaluation of skeletal morphology, an increased rate of rib anomalies/vertebral defect were identified. 76 Of interest, individuals with CHARGE and Kabuki syndromes demonstrate vertebral anomalies and individuals with CHARGE syndrome can have missing ribs. 77 Additional studies focused on the brain and behavior of these mice could demonstrate important changes in brain function and/or behavior given a recent report characterizing the expression profile and the neuroanatomical localization of HOXA5 in the fetal, postnatal, and adult brain. 75 They identified Hoxa5 transcripts in the medulla oblongata and the pons from fetal to adult stages, and in the thalamus and the cortex from postnatal stages through adulthood. They also demonstrated that Hoxa5 is transcribed in the adult cerebellum and that the HOXA5 protein is present in all the Hoxa5-expressing hindbrain nuclei in adulthood. This suggests that HOXA5 in these nuclei might be required for processes beyond the early developmental patterning and neuronal migration phases, including axonal growth and synapse formation during circuit establishment, refinement of neural circuits during early postnatal life in response to environmental cues, or adult synaptic plasticity. 75 82, 83 . SLITRK5 has been shown to function in synaptic adhesion and in tropomyosin receptor kinase B (TRKB) signaling upon brain-derived neurotrophic factor (BDNF) stimulation. 84 In Chd7 À/À mouse whole embryos, expression of SLITRK5 is decreased. 45 Mice with homozygous deletion of Slitrk5 develop an over-grooming phenotype and deficiencies in corticostriatal transmission as well as a reduction in glutamate receptor subunits. 85 We expect that dysregulation of SLITRK5, either gain or loss, could impact neuronal development due to its role in many tightly regulated processes at the synapse.
Epigenetic Targets Specific to CHARGE and Kabuki Syndromes One of the genes specific to the CHD7 LOF DNAm signature is FOXP2. In mice, FOXP2 has been shown to be expressed in the motor related circuitry in the brain, which controls craniofacial development including muscles of the face and striatal brain development. 36, 37 In mouse embryonic stem cells and neural progenitors, chromatin immunoprecipitation assays show that CHD7 binds to the Foxp2 promoter. 41 As mutations in FOXP2 have been identified in individuals with speech and language deficits, 86 it is possible that altered FOXP2 expression might contribute to the speech and language difficulties in individuals with CHARGE syndrome. Specific to the KMT2D LOF DNAm signature are CpG sites within the gene body of MYO1F. These sites are located in a CpG island carrying chromatin marks which classify the region as regulatory, specifically as a promoter or enhancer in different cell types. 38, 39 This unconventional myosin is expressed in the inner ear and heterozygous missense mutations in this gene have been identified in individuals with hereditary hearing loss.
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Overlapping Epigenetic Targets for KMT2D and KDM6A in Kabuki Syndrome Our observation that the single sample from with a KDM6A pathogenic mutation in the Validation cohort clustered with the pathogenic KMT2D samples suggests that these two genes regulate overlapping sets of genes. This is in keeping with evidence from earlier studies that showed these two proteins share HOX targets.
88
KDM6A, a histone demethylase, has been shown to interact with KMT2D as part of a multi-protein complex. 89 More recently, the majority of KDM6A target genes have been shown to be co-regulated by KMT2D. 90 Knockdown of the zebrafish orthologs of KMT2D and KDM6A confirmed the role of these proteins in craniofacial, heart, and brain development, providing direct evidence of the overlapping, functional roles of these genes in the development of tissues and organs affected in Kabuki syndrome. 91 DNAm analysis of additional samples with KDM6A pathogenic mutations will be required to assess for potentially overlapping yet distinct DNAm signatures. Such a study would also allow for a comparison of the target genes regulated by KMT2D and KDM6A furthering our understanding of the overlapping and distinct functions of these two genes in the etiology of Kabuki syndrome.
Potential for Therapeutic Interventions Based on Epigenetic Targets
As our knowledge of epigenetic regulation in neurodevelopmental disorders increases, so does the opportunity for therapeutic interventions. 
Conclusion
In this article, we present DNAm signatures for CHD7 and KMT2D in human blood cells which hold promise for translational clinical use. These signatures, which have a high degree of sensitivity and specificity, identify specific target genes in human blood cells regulated by CHD7 and KMT2D. Our findings provide evidence that CHARGE and Kabuki syndromes result from dysregulatrion of key genes involved embryonal development that are expressed in a tissue-specific manner. Future studies in developmental model systems such as human induced pluripotent stem cells will help to enhance our understanding of epigenetic regulation in diverse celltypes, including neuronal cells. The field of epigenomics offers a host of opportunities to positively impact precision medicine including a robust means of classifying pathogenicity of VUS and understanding disease pathophysiology in the context of genome-wide targets of epigenes. The identification of a multitude of gene-specific targets across the genome provides tangible opportunities to explore novel therapeutics to reverse neurodevelopmental deficits caused by epigenetic dysregulation.
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